Bryn Mawr Capital Management LLC Boosts Stake in Novartis AG (NYSE:NVS)

Bryn Mawr Capital Management LLC raised its holdings in Novartis AG (NYSE:NVS) by 2.2% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 12,995 shares of the company’s stock after acquiring an additional 274 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Novartis were worth $1,383,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in NVS. Frazier Financial Advisors LLC acquired a new stake in shares of Novartis during the 4th quarter valued at approximately $26,000. Private Ocean LLC acquired a new stake in Novartis in the first quarter valued at $25,000. Richardson Financial Services Inc. purchased a new position in shares of Novartis in the fourth quarter valued at $26,000. New Millennium Group LLC acquired a new position in shares of Novartis during the 2nd quarter worth $28,000. Finally, Clearstead Trust LLC boosted its position in shares of Novartis by 73.5% in the 1st quarter. Clearstead Trust LLC now owns 269 shares of the company’s stock worth $26,000 after buying an additional 114 shares in the last quarter. Hedge funds and other institutional investors own 13.12% of the company’s stock.

Novartis Trading Up 0.4 %

Shares of NVS stock opened at $120.89 on Friday. Novartis AG has a 1-year low of $92.19 and a 1-year high of $120.92. The firm’s 50-day simple moving average is $111.51 and its 200-day simple moving average is $103.86. The firm has a market cap of $247.10 billion, a P/E ratio of 16.31, a PEG ratio of 1.77 and a beta of 0.57. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.93 and a quick ratio of 0.72.

Novartis (NYSE:NVS) last issued its earnings results on Thursday, July 18th. The company reported $1.97 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.10. The firm had revenue of $12.87 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Novartis had a return on equity of 34.56% and a net margin of 33.76%. During the same quarter last year, the firm earned $1.83 earnings per share. As a group, equities analysts forecast that Novartis AG will post 7.48 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on NVS shares. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Novartis in a research report on Friday, July 19th. Barclays raised Novartis to a “strong sell” rating in a research report on Monday, June 24th. Jefferies Financial Group upped their price objective on Novartis from $121.00 to $122.50 and gave the company a “buy” rating in a research report on Tuesday, July 2nd. Finally, The Goldman Sachs Group began coverage on Novartis in a research report on Thursday, May 30th. They set a “buy” rating and a $120.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Novartis presently has an average rating of “Hold” and a consensus price target of $118.13.

Novartis Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.